RSC Advances



View Article Online

View Journal | View Issue

COMMUNICATION



Cite this: RSC Adv., 2014, 4, 53722

Total synthesis of (+)-swainsonine and (+)-8-episwainsonine⁺

Milos Trajkovic, Vesna Balanac, Zorana Ferjancic* and Radomir N. Saicic*

Received 12th September 2014 Accepted 14th October 2014

DOI: 10.1039/c4ra11978a

www.rsc.org/advances

Enantioselective synthesis of (+)-swainsonine was achieved in 9 steps, with 24% overall yield. The key feature of the synthesis is the tactical combination of reactions: organocatalyzed aldolization/reductive amination, which allows for a rapid construction of highly functionalized heterocyclic systems. In a similar way (+)-8-*epi*-swainsonine was synthesized (7 steps, 28%).

Iminosugars, also known as azasugars, or iminocyclitols, are a class of alkaloids that has attracted considerable attention from the scientific community, due to their promising biological activity.1 These compounds inhibit enzymes involved in carbohydrate processing, which may have therapeutic potential for treatment of various diseases, such as cancer, diabetes, obesity, or viral infections.1c Indolizidine alkaloids are an important subclass of this family,² where swainsonine (ent-1)³ occupies a prominent place. This alkaloid, first isolated in 1973,4 was found to be a potent inhibitor of mannosidases,5 and has entered in phase II clinical trials for the treatment of renal carcinoma.6 It was also found to be a potent and strain-selective inhibitor of infection by prions - infectious agents responsible for neurodegenerative disorders such as Creutzfeldt-Jacob disease and kuru.7 Intensive synthetic efforts toward this compound have resulted in more than 50 syntheses, most of them relying on a chiron approach, using sugars, amino acids, or hydroxy acids as starting compounds.8,9 Of interest is not only swainsonine, but also its structural analogues (including the optical antipode, which is a strong and specific inhibitor of naringinase),91,10 for the studies of structure activity relationship.11

We set out to develop an enantioselective synthesis of swainsonine that would start from achiral precursors, using a catalytic asymmetric approach. The retrosynthetic blueprint is represented in Scheme 1. Disconnection of the piperidine ring in 1 by reductive amination gives pyrrolidine derivative 2, which would be obtained by homologation of aldehyde 3. The synthetic predecessor of 3 - dioxolane 4 - should be a thermodynamically more stable isomer of 1,3-dioxane 5, on its turn obtainable by reductive amination of aldol 6. This latter compound would be assembled by an organocatalyzed¹² aldol addition of dioxanone (7)¹³ to amino aldehyde 8. The key feature of this synthetic concept would be the tactical combination of reactions: organocatalyzed aldolization/reductive amination, which we recently applied in the synthesis of hyacinthacine analogues.¹⁴ Both enantiomers of swainsonine would be available from the same starting compounds, using enantiomeric organocatalysts.

The synthesis commenced with (*S*)-proline-catalyzed aldol addition of dioxanone (7) to aminoacetaldehyde derivative $\mathbf{8}$, which produced the desired adduct $\mathbf{6}$ in 66% yield, as a single diastereoisomer (Scheme 2). For the reasons of atom-economy,



Scheme 1 Retrosynthetic analysis of (+)-swainsonine (1).

Faculty of Chemistry, University of Belgrade, Studentski trg 16, POB 51, 11158 Belgrade 118, Serbia. E-mail: rsaicic@chem.bg.ac.rs

 [†] Electronic supplementary information (ESI) available: Experimental procedures, spectral data and copies of NMR spectra for all compounds, CIF file for compound
 5. CCDC 1009272. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c4ra11978a



Scheme 2 Total synthesis of (+)-swainsonine (1) and (+)-8-epi-swainsonine (13).

we also attempted to perform the aldol addition with a singleprotected Cbz-aminoacetaldehyde (i.e., substituting hydrogen for benzyl in compound 8). These attempts gave inferior results: lower diastereoselectivity, extended reaction time, incomplete conversion and the low yield (20-30%); in addition, the corresponding aldol product was unstable and decomposed on purification. Upon exposure to a hydrogen atmosphere in the presence of palladium on charcoal, aldol 6 underwent double deprotection followed by a reductive amination, to give a pyrrolidine derivative which was reprotected in situ and isolated as a Cbz-derivative 5. The product was obtained as a mixture of two easily separable diastereoisomers with the predominance of the desired one (5: 71%; epi-5 (not represented): 6%), corresponding to the hydrogen delivery from the sterically less shielded, convex face of the bicyclic imine intermediate. The absolute configuration of this compound was confirmed by a singlecrystal X-ray analysis.15 Acetone-derived dioxolanes are known to be more stable than the corresponding dioxanes; therefore, 5 was isomerized in the presence of a catalytic amount of p-TsOH to primary alcohol 4, which was further oxidized with Dess-Martin periodinane to aldehyde 3. Homologation of 3 was accomplished in high yield via addition of Grignard reagent 9, with the formation of a single diastereoisomer 10. The observed stereochemical outcome of the reaction can be explained by the coordination of the metal with the carbamate oxygen followed by the nucleophilic attack from the sterically less shielded face.^{16,11d,e} Exposure of **10** to the hydrogenation conditions in 2



Scheme 3 Side reactions during attempted reductive amination of 12.

M HCl resulted in reductive amination and produced (+)-8-episwainsonine (13) in high yield. The configurational inversion of the newly created secondary alcohol stereocenter in 10, as required for the synthesis of 1, was accomplished under modified Mitsunobu conditions: the Cbz group served as an internal nucleophile, thus obviating the need for the addition of carboxylic acid, which is usually used as an external nucleophile in the reactions of this type. After the hydrolysis of cyclic carbamate 11, aminoacetal 12 was subjected to the hydrogenation conditions in highly acidic medium, to provide in excellent vield (+)-swainsonine (1) identical to the natural product in all respect (except for the sense of optical rotation). It is of note that for the cyclization of 12 to occur, a fine balance between the acidity and the reducing power of the reaction medium is required. An attempt to hydrolyze the acetal functionality in 12 by treatment with 2 M HCl resulted in the formation of dimeric compound 14 (64%, Scheme 3).17 To our surprise, catalytic hydrogenation of 12 under mildly acidic conditions gave Nethylated product 15 (37%, Scheme 3).18

Conclusions

To summarize, total synthesis of (+)-swainsonine (1) was achieved from the commercially available achiral precursors in 9 steps with 24% overall yield, which compares favorably (in terms of yield and step-economy) with all previous asymmetric syntheses of this compound. In addition, (+)-8-*epi*-swainsonine was also synthesized by the shortest route reported so far (7 steps, 28% overall yield). The key feature of the syntheses described is the tactical combination of reactions: organocatalyzed aldolization/reductive amination, which allows for an expedient entry into optically pure heterocycles.

Acknowledgements

This work was supported by the Serbian Ministry of Education, Science and Technological Development (Project no. 172027) and by the Serbian Academy of Sciences and Arts (Project no. F193).

Notes and references

 (a) N. Asano, R. J. Nash, R. J. Molyneux and G. W. J. Fleet, *Tetrahedron: Asymmetry*, 2000, **11**, 1645; (b) A. A. Watson, G. W. J. Fleet, N. Asano, R. J. Molyneux and R. J. Nash, *Phytochemistry*, 2001, **56**, 265; (c) *Iminosugars: From* **RSC Advances**

Synthesis to Therapeutic Applications, ed. P. Compain and O. R. Martin, Wiley, Chichester, 2007; (d) R. J. Nash, A. Kato, C.-Y. Yu and G. W. J. Fleet, *Future Med. Chem.*, 2011, **3**, 1513.

- 2 (a) J. P. Michael, Nat. Prod. Rep., 1997, 14, 619; (b)
 J. P. Michael, Nat. Prod. Rep., 2007, 24, 191; (c)
 J. P. Michael, Nat. Prod. Rep., 2008, 25, 139.
- 3 M. J. Schneider, F. S. Ungermach, H. P. Broquist and T. M. Harris, *Tetrahedron*, 1983, **39**, 29.
- 4 F. P. Guengerich, S. J. DiMari and H. P. Broquist, *J. Am. Chem. Soc.*, 1973, **95**, 2055.
- 5 (a) P. R. Dorling, C. R. Huxtable and S. M. Colegate, *Biochem. J.*, 1980, 191, 649; (b) A. D. Elbein, R. Solf, P. R. Dorling and K. Vosbeck, *Proc. Natl. Acad. Sci. U. S. A.*, 1981, 78, 7393; (c) D. R. Tulsiani, T. M. Harris and O. J. Touster, *Biol. Chem.*, 1982, 257, 7936; (d) G. P. Kaushal, T. Szumilo, I. Pastuszak and A. D. Elbein, *Biochemistry*, 1990, 29, 2168; (e) Y. F. Liao, A. Lal and K. W. Moreman, *J. Biol. Chem.*, 1996, 271, 28348.
- 6 P. E. Shaheen, W. Stadler, P. Elson, J. Knox, E. Winquist and R. M. Bukowski, *Invest. New Drugs*, 2005, **23**, 577.
- 7 J. Li, S. Browning, S. P. Mahal, A. M. Oelschlegel and C. Weissmann, *Science*, 2010, **327**, 869.
- 8 For review articles on total syntheses of swainsonine and its analogues prior to 2005, see: (*a*) E. A. Nemr, *Tetrahedron*, 2000, **56**, 8579; (*b*) S. G. Pyne, *Curr. Org. Synth.*, 2005, **2**, 39.
- 9 For total syntheses of swainsonine since 2005, see: From carbohydrates: (a) P. K. Sharma, R. N. Shah and J. P. Carver, Org. Process Res. Dev., 2008, 12, 831; (b) M. A. Alam, A. Kumar and Y. D. Vankar, Eur. J. Org. Chem., 2008, 4972; (c) D. J. Wardrop and E. G. Bowen, Org. Lett., 2011, 13, 2376, From α -amino acids: (d) S. Chooprayoon, C. Kuhakarn, P. Tuchinda, V. Reutrakul and M. Pohmakotr, Org. Biomol. Chem., 2011, 9, 531, From other sources: (e) R. Martin, C. Murruzzu, M. A. Pericas and A. Riera, J. Org. Chem., 2005, 70, 2325; (f) G. Heimgartner, D. Raatz and O. Reiser, Tetrahedron, 2005, 61, 643; (g) H. Guo and G. A. O'Doherty, Org. Lett., 2006, 8, 1609; (h) J. Ceccon, A. E. Greene and J.-F. Poisson, Org. Lett., 2006, 8, 4739; (i) A. E. Hakansson, J. van Ameijde, G. Horne, R. J. Nash, M. R. Wormald, A. Kato, G. S. Besra, S. Gurcha and G. W. J. Fleet, Tetrahedron Lett., 2008, 49, 179; (j) H. Guo and G. A. O'Doherty, Tetrahedron, 2008, 64, 304; (k) G.-F. Shi, J.-Q. Li, X.-P. Jiang and Y. Cheng, Tetrahedron, 2008, 64, 5005; (1) Y.-S. Tian, J.-E. Joo, B.-S. Kong, V.-T. Pham, K.-Y. Lee and W.-H. Ham, J. Org. Chem., 2009, 74, 3962; (m) J. Louvel, F. Chemla, E. Demont, F. Ferreira and A. Perez-Luna, Org. Lett., 2011, 13, 6452; (n) M.-J. Chen and Y.-M. Tsai, Tetrahedron, 2011, 67, 1564; (o) G. Archibald, C. Lin, P. Boyd, D. Barker and V. Caprio, J. Org. Chem., 2012, 77, 7968; (p) P. Singh, S. K. Manna and G. Panda, Tetrahedron, 2014, 70, 1363, formal syntheses; (q) D. Díez, M. T. Beneitez, M. J. Gil, R. F. Moro, I. S. Marcos, N. M. Garrido, P. Basabe and J. G. Urones, Synthesis, 2005, 565; (r) C. W. G. Au and S. G. Pyne, J. Org. Chem., 2006, 71, 7097; (s) I. Dechamps, D. Gomez Pardo and J. Cossy, Tetrahedron, 2007, 63, 9082; (t) H. Y. Kwon, C. M. Park, S. B. Lee, J.-H. Youn and S. H. Kang, Chem.-Eur. J., 2008, 14,

1023; (*u*) R. W. Bates and M. R. Dewey, *Org. Lett.*, 2009, **11**, 3706; (*v*) S. J. Oxenford, S. P. Moore, G. Carbone, G. Barker, P. O'Brien, M. R. Shipton, J. Gilday and K. R. Campos, *Tetrahedron: Asymmetry*, 2010, **21**, 1563; (*w*) H. G. Choi, J. H. Kwon, J. C. Kim, W. K. Lee, H. Eum and H.-J. Ha, *Tetrahedron Lett.*, 2010, **51**, 3284; (*x*) S. N. Murthy and Y. V. D. Nageswar, *Synthesis*, 2011, 755; (*y*) R. W. Bates, M. R. Dewey, C. H. Tang, S. B. Safii, Y. Hong, J. K. H. Hsieh and P. S. Siah, *Synlett*, 2011, **14**, 2053; (*z*) Q. R. Li, G. R. Dong, S. J. Park, Y. R. Hong, I. S. Kim and Y. H. Jung, *Eur. J. Org. Chem.*, 2013, 4427; (*aa*) V. Dhand, J. A. Draper, J. Moore and R. Britton, *Org. Lett.*, 2013, **15**, 1914.

- 10 B. Davis, A. A. Bell, R. J. Nash, A. A. Watson, R. C. Griffiths, M. G. Jones, C. Smith and G. W. J. Fleet, *Tetrahedron Lett.*, 1996, 37, 8565.
- selected examples of synthetic analogues of 11 For swainsonine, see: (a) W. H. Pearson and L. Guo, Tetrahedron Lett., 2001, 42, 8267; (b) T. Fujita, H. Nagasawa, Y. Uto, T. Hashimoto, Y. Asakawa and H. Hori, Org. Lett., 2004, 6, 827; (c) A. Tinarelli and C. Paolucci, J. Org. Chem., 2006, 71, 6630; (d) A. J. Murray and P. J. Parsons, Synlett, 2006, 1443; (e) A. J. Murray, P. J. Parsons and P. Hitchcock, Tetrahedron, 2007, 63, 6485; (f) J. Bi and V. K. Aggarwal, Chem. Commun., 2008, 120; (g) X.-L. Wang, W.-F. Huang, X.-S. Lei, B.-G. Wei and G.-Q. Lin, Tetrahedron, 2011, 67, 4919; (h) H. K. Zhang, S. Q. Xu, J. Zhuang, J. Ye and P. Q. Huang, Tetrahedron, 2012, 68, 6656; (i) B. K. Lee, H. G. Choi, E. J. Roh, W. K. Lee and T. Sim, Tetrahedron Lett., 2013, 54, 553; (j) P. Singh and G. Panda, RSC Adv., 2014, 4, 2161.
- 12 For selected review articles on organocatalysis, see: (a)
 P. I. Dalko and L. Moisan, *Angew. Chem., Int. Ed.*, 2004, 43, 5138; (b) J. Seayad and B. List, *Org. Biomol. Chem.*, 2005, 3, 719; (c) D. W. C. MacMillan, *Nature*, 2008, 455, 304.
- 13 For organocatalyzed aldol reactions with dioxanone, see: (a)
 J. T. Suri, D. B. Ramachary and C. F. Barbas III, Org. Lett., 2005, 7, 1383; (b) D. Enders and C. Grondal, Angew. Chem., Int. Ed., 2005, 44, 1210; (c) I. Ibrahem and A. Cordova, Tetrahedron Lett., 2005, 46, 3363; (d) C. Grondal and D. Enders, Tetrahedron, 2006, 62, 329; (e) J. T. Suri, S. Mitsumori, K. Albertshofer, F. Tanaka and C. F. Barbas III, J. Org. Chem., 2006, 71, 3822, for a recent review on organocatalyzed aldol reactions, see; (f) V. Bisai, A. Bisai and V. K. Singh, Tetrahedron, 2012, 68, 4541.
- 14 J. Marjanovic, V. Divjakovic, R. Matovic, Z. Ferjancic and R. N. Saicic, *Eur. J. Org. Chem.*, 2013, 5555.
- 15 ESI.†
- 16 N. Ikota and A. Hanaki, Chem. Pharm. Bull., 1990, 38, 2712.
- 17 T. Fujita, H. Nagasawa, Y. Uto, T. Hashimoto, Y. Asakawa and H. Hori, *Org. Lett.*, 2004, **6**, 827.
- 18 (a) For an example of *N*-methylation under similar reaction conditions, see: B. P. Bashyal, G. W. J. Fleet, M. J. Gough and P. W. Smith, *Tetrahedron*, 1987, 43, 3083; (b) For a review article on this transformation (borrowing hydrogen mechanism), see: M. H. S. A. Hamid, P. A. Slatford and J. M. J. Williams, *Adv. Synth. Catal.*, 2007, 349, 1555.